Jeffrey M. Gallagher is CEO of Virginia Bio, the statewide trade group of the life sciences industry in the Commonwealth of Virginia. Virginia Bio connects and supports companies, universities, entrepreneurs, investors, students, clinicians, data scientists, service professionals and patients to accelerate the discovery, commercialization and clinical application of bioscience products and services — from biopharmaceuticals to medical devices and diagnostics, digital and mobile health, bioinformatics and big data, and innovative health care solutions on one hand, to agricultural and industrial bioscience on the other. In this role, he is the industry’s principal spokesperson before state and federal policy makers, and to the public. He serves on numerous state and university technology commercialization grant review, policy and industry leadership panels.
Previously, Mr. Gallagher was a co-founder, VP and General Counsel for Lyotropic Therapeutics, Ashland, Virginia, a small specialty pharmaceutical company. He earlier practiced corporate law, focusing on new technology company formation, international business (managing the firm’s US and foreign based China practice), and intellectual property transactions, including biotechnology-based companies and university spinouts. He was a co-founder and longtime chairman of the Richmond-based nonprofit World Pediatric Project, and chairs its Richmond Board. He is vice chair of Virginia Rep, the state’s largest dramatic performing arts organization. He is a founding director of the Virginia Law Enforcement Assistance Program, which helps police officers overcome debilitating trauma suffered in the line of duty. He holds a bachelor of arts degree cum laude in government from Harvard, a J.D. from the University of Wisconsin Law School, and an LL.M in Public International Law from the University of Virginia School of Law, where he was a Ford Foundation fellow.